Aviso Financial Inc. Reduces Stock Position in Boston Scientific Corporation $BSX

Aviso Financial Inc. trimmed its holdings in shares of Boston Scientific Corporation (NYSE:BSX) by 9.4% in the second quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The fund owned 14,901 shares of the medical equipment provider’s stock after selling 1,540 shares during the period. Aviso Financial Inc.’s holdings in Boston Scientific were worth $1,601,000 as of its most recent filing with the Securities and Exchange Commission (SEC).

A number of other hedge funds have also made changes to their positions in the business. Bessemer Group Inc. boosted its holdings in Boston Scientific by 14,391.8% in the second quarter. Bessemer Group Inc. now owns 2,919,801 shares of the medical equipment provider’s stock valued at $313,618,000 after purchasing an additional 2,899,653 shares in the last quarter. Vanguard Group Inc. raised its holdings in Boston Scientific by 1.9% during the second quarter. Vanguard Group Inc. now owns 137,134,110 shares of the medical equipment provider’s stock worth $14,729,575,000 after purchasing an additional 2,545,381 shares in the last quarter. Price T Rowe Associates Inc. MD lifted its position in shares of Boston Scientific by 18.6% during the 1st quarter. Price T Rowe Associates Inc. MD now owns 10,610,487 shares of the medical equipment provider’s stock worth $1,070,387,000 after buying an additional 1,664,108 shares during the last quarter. Swedbank AB boosted its holdings in shares of Boston Scientific by 114.5% in the 2nd quarter. Swedbank AB now owns 2,819,249 shares of the medical equipment provider’s stock valued at $302,816,000 after buying an additional 1,505,019 shares in the last quarter. Finally, Goldman Sachs Group Inc. boosted its holdings in shares of Boston Scientific by 10.8% in the 1st quarter. Goldman Sachs Group Inc. now owns 14,143,332 shares of the medical equipment provider’s stock valued at $1,426,779,000 after buying an additional 1,383,524 shares in the last quarter. Hedge funds and other institutional investors own 89.07% of the company’s stock.

Wall Street Analyst Weigh In

BSX has been the topic of several research analyst reports. Robert W. Baird lifted their price target on shares of Boston Scientific from $123.00 to $128.00 and gave the stock an “outperform” rating in a research note on Wednesday, October 1st. Needham & Company LLC reiterated a “buy” rating and set a $121.00 target price on shares of Boston Scientific in a research report on Friday, October 17th. Leerink Partners boosted their target price on Boston Scientific from $127.00 to $128.00 and gave the company an “outperform” rating in a report on Wednesday, October 1st. BTIG Research reissued a “buy” rating and issued a $132.00 target price on shares of Boston Scientific in a research report on Friday. Finally, UBS Group raised their price target on Boston Scientific from $135.00 to $140.00 and gave the stock a “buy” rating in a research note on Thursday, October 23rd. Two equities research analysts have rated the stock with a Strong Buy rating, twenty-one have given a Buy rating and two have given a Hold rating to the company’s stock. According to MarketBeat.com, Boston Scientific currently has an average rating of “Buy” and an average target price of $123.77.

Insider Buying and Selling

In related news, EVP Joseph Michael Fitzgerald sold 50,000 shares of Boston Scientific stock in a transaction that occurred on Monday, November 3rd. The stock was sold at an average price of $99.47, for a total value of $4,973,500.00. Following the sale, the executive vice president directly owned 178,342 shares in the company, valued at $17,739,678.74. The trade was a 21.90% decrease in their ownership of the stock. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available through this link. Also, Director Ellen M. Zane sold 12,891 shares of the stock in a transaction on Thursday, November 6th. The stock was sold at an average price of $98.28, for a total value of $1,266,927.48. Following the completion of the transaction, the director owned 24,134 shares of the company’s stock, valued at $2,371,889.52. The trade was a 34.82% decrease in their position. The SEC filing for this sale provides additional information. Insiders sold a total of 175,782 shares of company stock worth $17,742,314 in the last ninety days. 0.50% of the stock is owned by corporate insiders.

Boston Scientific Stock Performance

Shares of BSX opened at $97.97 on Tuesday. The stock has a market capitalization of $145.23 billion, a P/E ratio of 52.39, a P/E/G ratio of 2.02 and a beta of 0.58. The company has a debt-to-equity ratio of 0.49, a quick ratio of 0.82 and a current ratio of 1.37. Boston Scientific Corporation has a 1 year low of $85.98 and a 1 year high of $109.50. The company’s fifty day moving average is $98.93 and its two-hundred day moving average is $102.31.

Boston Scientific (NYSE:BSX) last released its earnings results on Wednesday, October 22nd. The medical equipment provider reported $0.75 EPS for the quarter, topping the consensus estimate of $0.71 by $0.04. Boston Scientific had a net margin of 14.43% and a return on equity of 19.74%. The company had revenue of $5.07 billion during the quarter, compared to analysts’ expectations of $4.97 billion. During the same quarter last year, the business earned $0.63 EPS. The business’s revenue was up 20.3% on a year-over-year basis. Boston Scientific has set its FY 2025 guidance at 3.020-3.040 EPS. Q4 2025 guidance at 0.770-0.790 EPS. On average, sell-side analysts predict that Boston Scientific Corporation will post 2.85 earnings per share for the current year.

About Boston Scientific

Boston Scientific Corporation develops, manufactures, and markets medical devices for use in various interventional medical specialties worldwide. It operates through two segments, MedSurg and Cardiovascular. The company offers devices to diagnose and treat gastrointestinal and pulmonary conditions, such as resolution clips, biliary stent systems, stents and electrocautery enhanced delivery systems, direct visualization systems, digital catheters, and single-use duodenoscopes; devices to treat urological conditions, including ureteral stents, catheters, baskets, guidewires, sheaths, balloons, single-use digital flexible ureteroscopes, holmium laser systems, artificial urinary sphincter, laser system, fiber, and hydrogel systems; and devices to treat neurological movement disorders and manage chronic pain, such as spinal cord stimulator system, proprietary programming software, radiofrequency generator, indirect decompression systems, practice optimization tools, and deep brain stimulation system.